• 1
    Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001;12: 848855.
  • 2
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002; 39: 10881095.
  • 3
    Siu CWD, Chan TM, Li FK et al. Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or disease in cadaveric renal allograft recipients. Transplant Proc 2000; 32: 19321934.
  • 4
    Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental mycophenolate mofetil renal transplantation Study Group. Transplantation 1998; 65: 14501454.
  • 5
    Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on CMV disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325330.
  • 6
    Flechner SM, Avery RK, Fisher R et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66: 16821688.
  • 7
    Lowance D, Neumayer H, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 14621470.
  • 8
    Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721729.
  • 9
    Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 18431846.
  • 10
    Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 11741180.
  • 11
    Kaufman DB, Leventhal JR, Gallon LG et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001; 72: 19401945.
  • 12
    Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 28112815.
  • 13
    Martin DF, Siera-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retnitis. N Engl J Med 2002; 346: 11191126.
  • 14
    Czock D, Scholle C, Rasche FM, Schaarschmidt, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142150.
  • 15
    Paya CV. A randomized, double-blind, double dummy, active comparator controlled multi-center study of the efficacy and safety of valganciclovir vs oral ganciclovir for prevention of CMV disease in 372 high-risk (D+/R-) heart, liver, and kidney recipients. Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002: San Diego, CA (Abstract).
  • 16
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645649.
  • 17
    Lurain NS, Bhorade SM, Pursell KJ et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760768.
  • 18
    Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 7381.
  • 19
    Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 8386.
  • 20
    Humar A, Uknis M, Carlone-Jambor C et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 9497.